Manufacturer Provide Raw Material Dapagliflozin Propanediol CAS 461432-26-8 Daglican Dapagliflozin Powder

Introduction

Product Name: Dapagliflozin

Other Name :DAPAGLIFLOZIN BASE;Daglican;Dapagliflozi

CAS NO:461432-26-8

Purity: 99%min
Appearance:White crystalline powder

Molecular formula:C21H25ClO6

MW:408.88

Melting Point :55-58°C

Boiling Point :609.0±55.0 °C(Predicted)

Density:1.349

Storage :Keep in dark place,Inert atmosphere,Room temperature

Dapagliflozin is a new type of antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the European Medicines Agency (EMA) on November 12, 2012 and is the first to be approved. SGLT2 inhibitors for the treatment of type 2 diabetes are important candidates for the treatment of diabetes. They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Application

Dapagliflozin is a drug used to treat type 2 diabetes.It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.